You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The guidelines caution that there are "significant limitations" in the interpretation of polygenic risk scores and they should not be used in patient management.
The nationwide study will enroll prostate cancer patients who do and don't meet current guidelines and assess how access to genetic information impacts their care.
The society recommends routine use of multigene NGS for a handful of metastatic cancers, as well as in the context of clinical trials at academic centers.
The center said because universal testing of students and staff "has not been systematically studied," it is unclear what benefits it may confer.
The updated guidelines now also highlight the use of PCR and next-generation sequencing to determine microsatellite instability.
Its authors said the guidance provides a focus on how clinicians can get the most efficacy and highest quality results from implementing best practices.
The group said the recommendations aim to standardize and improve warfarin response genotyping assays.
The group now states that men with unfavorable intermediate-risk or high-risk disease can consider testing with Myriad's Prolaris or GenomeDx's Decipher.
Amid rapid adoption of multi-gene panels, ACMG experts are seeing some doctors and patients taking actions they shouldn't.
Absent sufficient evidence to support genetic testing for all patients, the group recommended following existing guidelines, which are based on clinical factors.